A recent study by the University of California-Davis in the US has revealed promising results for primary sclerosing cholangitis (PSC), a rare liver disease. The research focused on a monoclonal antibody named nebokitug, known for its anti-inflammatory and anti-fibrotic properties, showing it to be safe and potentially effective for PSC patients. Published in the American Journal of Gastroenterology, the study brings hope to individuals with PSC, as current treatment options are limited to liver transplantation.
Christopher Bowlus, the chief of Gastroenterology and Hepatology at UC Davis Health, expressed optimism about the trial results, stating that nebokitug could significantly impact the lives of PSC patients by reducing fibrosis and inflammation, leading to better outcomes. Patients with PSC, a condition characterized by bile duct inflammation and scarring, often face challenges due to the lack of effective therapies.
Primary sclerosing cholangitis (PSC) is a chronic liver disease that causes damage to the bile ducts, impairing the flow of bile from the liver to the small intestine. This buildup of bile can result in liver injury over time, with symptoms such as fatigue, itching, and jaundice. While the exact cause of PSC remains unclear, its association with inflammatory bowel disease suggests a connection between intestinal inflammation and liver damage.
Nebokitug, a synthetic antibody designed to target the protein CCL24, aims to counteract inflammation and scarring processes in the liver. Elevated levels of CCL24 in PSC patients contribute to liver damage, making it a key target for therapeutic intervention. The Phase 2 trial, involving 76 PSC patients from five countries, demonstrated the safety and tolerability of nebokitug, with notable improvements in liver stiffness and fibrosis markers observed, particularly in patients with advanced liver scarring.
